MT-125

Myosin Therapeutics Inc. · Phase 1 active Small molecule

At a glance

Generic name	MT-125
Sponsor	Myosin Therapeutics Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 1 Study of the Safety and Tolerability of MT-125 in GBM Patients (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MT-125 CI brief — competitive landscape report
MT-125 updates RSS · CI watch RSS
Myosin Therapeutics Inc. portfolio CI